MCM
TCRT icon

MAI Capital Management’s Alaunos Therapeutics TCRT Stock Holding History

MAI Capital Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6
Closed -$12 – 3573
2024
Q4 		$12 Buy
+6
New +$13 ﹤0.01% 3474

Other funds holding TCRT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

MAI Capital Management's TCRT Position: Q1 2025 in Review

MAI Capital Management sold out of Alaunos Therapeutics (TCRT) in Q1 2025, closing a stake of 6 shares — an estimated $12 sold.

MAI Capital Management first reported a position in TCRT in Q4 2024 and held it in 1 quarter. The position peaked at $12 in Q4 2024. 29 funds tracked by Wall St. Rank hold TCRT as of Q1 2025.

  • MAI Capital Management reported no remaining Alaunos Therapeutics position as of Q1 2025 after selling out during the quarter.
  • MAI Capital Management sold 6 Alaunos Therapeutics shares in Q1 2025, an estimated $12.
  • MAI Capital Management first reported a position in Alaunos Therapeutics in Q4 2024 and held it in 1 quarter.
  • MAI Capital Management's Alaunos Therapeutics position peaked at $12 in Q4 2024.
  • 29 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2025.

Based on MAI Capital Management's 13F filing for Q1 2025, filed 15 May 2025.